Rocco Scarmozzino

Dr. Rocco Scarmozzino

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
RSRocco Scarmozzino
Rocco Scarmozzino
GZGiovanna Zanoni
Giovanna Zanoni
AAAlessandra Arcolaci
Alessandra Arcolaci
RCRachele Ciccocioppo
Rachele Ciccocioppo
Celiac disease (CD) is an autoimmune disorder caused by gluten intake in genetically predisposed individuals. This article provides an overview of the available data on the risks of infectious diseases and the mechanisms involved in CD, including a detailed analysis of vaccine efficacy, immunogenicity, and safety. The published articles were retrieved from the PubMed database using the terms “celiac disease”, “efficacy”, “hyposplenism”, “immune response”, “infections”, “immunization”, “immunogenicity”, “safety”, “vaccination”, and “vaccine”. CD can be associated with several autoimmune diseases, including selective immunoglobulin A deficiency (SIgAD), altered mucosal permeability, and hyposplenism. These conditions entail an increased risk of infections, which can be prevented by targeted vaccinations, although specific recommendations on immunization practices for subjects with CD have not been released. Regarding vaccinations, the immune response to the Hepatitis B virus (HBV) vaccine can be impaired in patients with CD; therefore, proposed strategies to elicit and maintain protective specific antibody titers are summarized. For patients with conditions that put them at risk of infections, vaccinations against Pneumococcus and other encapsulated bacteria should be recommended. Based on the available evidence, the Rotavirus vaccine offered to children could be useful in preventing CD in at-risk subjects. Overall, except for the HBV vaccine, vaccine efficacy in patients with CD is comparable to that in the general population, and no safety concerns have arisen.

5 June 2025 in Vaccine
Verified
Journal Article
Closed access
AAAlessandra Arcolaci
Alessandra Arcolaci
LGLucia Guidolin
Lucia Guidolin
EOElisa Olivieri
Elisa Olivieri
MBMaria Beatrice Bilò
Maria Beatrice Bilò
PBPatrizia Bonadonna
Patrizia Bonadonna
GZGiovanna Zanoni
Giovanna Zanoni